|Market Size in 2018||Market Forecast in 2025||Growth Rate (in %)||Base Year|
|USD 13.81 billion||USD 17.65 billion||CAGR at 3.6%.||2018|
Chemotherapy-Induced Myelosuppression T Market
In Global Chemotherapy-Induced Myelosuppression Treatment Market Report, The report covers forecasts and analyses for the chemotherapy-induced myelosuppression treatment market on a global and regional level. The study provides historic data from 2023 along with forecasts from 2023 to 2030 based on revenue (USD Million). The study includes drivers and restraints for the chemotherapy-induced myelosuppression treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the chemotherapy-induced myelosuppression treatment market on a global as well as regional level.
In order to give the users of this report a comprehensive view on the chemotherapy-induced myelosuppression treatment market we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the chemotherapy-induced myelosuppression treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new indication launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the chemotherapy-induced myelosuppression treatment market on global and regional basis.
The study provides a crucial view on the chemotherapy-induced myelosuppression treatment by segmenting the market based on indication, route of administration, drug class, distribution channel and region. All the segments of the chemotherapy-induced myelosuppression treatment market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.
Suppression of bone marrow is termed as myelosuppression. Myelosuppression leads to decreased blood cells production as a result of reduced activity of bone marrow. This may cause decrease in all types of blood cells such as red blood cells (RBCs), white blood cells (WBCs) and platelets or any one. Pancytopenia refers to decrease in all three types of blood cells. Myelosuppression is most common side effect of chemotherapy. Chemotherapy may lead to mild to severe myelosuppression. Severe myelosuppression can be fatal and needs medical attention. Various symptoms of myelosuppression include fatigue, dizziness, shortness of breath, anemia in case of decrease in red blood cells, infection such as cough, chills, fever etc. in case of decrease in white blood cells. Decrease in platelet count may lead to thrombocytopenia.
The demand for chemotherapy-induced myelosuppression treatment market is driven by availability of advanced treatment options like chemotherapy, surgeries, radiotherapy, increasing preference for chemotherapy for cancer treatment, promising drug pipelines, increasing prevalence of cancer across the globe, increasing awareness among patients, increasing healthcare expenditure and increasing disposable income, launch of cost effective biosimilars. However, loss of patent exclusivity and intense competition may hinder the market growth. Extensive drug pipeline and focus of pharmaceutical companies on development of safe and efficient chemotherapy-induced myelosuppression treatment drugs will bring new growth opportunities for market players over the forecast period.
Based on indication, the global chemotherapy-induced myelosuppression treatment market is bifurcated into anemia, neutropenia, and thrombocytopenia. The neutropenia indication segment accounted for the largest market share in 2018 and is expected to retain its dominance over the forecast period. Neutropenia is most common side effect resulting from myelosuppression treatment. The severity and complications of neutropenia may be fatal and thus attribute to a large share. The thrombocytopenia segment will register the highest growth over the forecast period.
Based on drug class market is segmented into thrombopoietin agents, erythropoietin stimulating agents, iron supplements, growth factors and others. Growth factors drug class segment held dominating market share in 2018. Whereas erythropoietin stimulating agents drug class segment will witness the highest growth rate over the forecast period.
Based on the route of administration, the global chemotherapy-induced myelosuppression treatment market is categorized into injectable and oral. The injectable administration route segment held the largest market share in 2018. This is due to their higher therapeutic availability compared to oral drugs.
The distribution channel segment of the TNF inhibitor drugs market is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Retail pharmacies held largest revenue share in 2018 among all distribution channels. Online pharmacies are expected to witness rapid growth in the years to come.
|Report Attributes||Report Details|
|Report Name||Chemotherapy-Induced Myelosuppression Treatment Market Research Report|
|Market Size in 2018||USD 13.81 billion|
|Market Forecast in 2025||USD 17.65 billion|
|Growth Rate||CAGR of 3.6%.|
|Number of Pages||126|
|Key Companies Covered||Teva Pharmaceutical Industries Ltd., Amgen Inc., Janssen Global Services, LLC, Pfizer Inc., Mylan NV, Mission Pharmacal Company, Myelo Therapeutics GmbH, Dova Pharmaceuticals, Partner Therapeutics, Inc. and Novartis AG among others.|
|Segments Covered||By Indication,BY Drug Class,BY Route of Administration,By Distribution Channel AND BY Regional|
|Regions Covered||North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)|
|Historical Year||2018 to 2025|
|Forecast Year||2018 - 2025|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
North America dominated the global chemotherapy-induced myelosuppression treatment market in 2018. Favorable reimbursement policies, strong commercial sales, a large patient pool, the presence of key players, and growing awareness are major factors driving the growth in this region. Europe was the second-largest regional market in terms of revenue share. Increasing prevalence of cancer, availability of developed infrastructure, and growing awareness are some of the factors that boost the market growth in this region. Asia Pacific region will be the rapidly growing market for chemotherapy-induced myelosuppression treatment. Economic development, increasing geriatric population base and cancer prevalence, healthcare infrastructure improvement, increasing healthcare spending and disposable income, and growing awareness are important factors attributing to the rapid growth in this region. On the other hand Latin America will experience moderate growth in the coming years. Middle East and Africa will register slower growth in the years to come.
Major players in the chemotherapy-induced myelosuppression treatment market are:
Global Chemotherapy-Induced Myelosuppression Treatment Market: Indication
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Drug Class
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Route of Administration
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Distribution Channel